Journal Article
Randomized Controlled Trial
Add like
Add dislike
Add to saved papers

[Monitoring of neurotrophic factors and cognitive function in patients with traumatic brain injury].

AIM: To study the neurological and cognitive status in comparison to the quantitative content of blood serum neurotrophic factors of patients with acute and long-term brain injury during treatment with cerebrolysin.

MATERIAL AND METHODS: Eighty patients, 56 men and 24 women, aged from 18 to 64 years, were examined in acute and long-term periods of the brain injury of moderate severity. An open, comparative, randomized study was performed before and after treatment with cerebrolysin.

RESULTS AND CONCLUSION: Cognitive impairment, dysregulation type in the acute and long-term brain injury of mild to moderate severity was associated with the low content of brain-derived neurotrophic factor. These disorders were clinically more pronounced in patients with the damage of the frontal and temporal lobes. After treatment with cerebrolysin, a significant positive dynamics on the scale of frontal dysfunction and increased levels of serum brain-derived neurotrophic factor were identified.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app